Complete resolution of urgency urinary incontinence

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%

Women receiving onabotulinumtoxinA were significantly more likely to achieve complete resolution of urgency urinary incontinence compared to those receiving anticholinergic therapy (27% vs 13%, P=0.00

Effect: improvement; 27% vs 13%